Related Experiment Video

Updated: Mar 17, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Selumetinib in the treatment of non-small-cell lung cancer

Reyes Bernabé1,2, Ana Patrao1, Louise Carter1

  • 1The Christie NHS Foundation Trust, Manchester, UK.

Future Oncology (London, England)
|July 29, 2016
PubMed

Insights

Selumetinib, a MEK1/2 inhibitor, shows efficacy in KRAS-mutant non-small-cell lung cancer (NSCLC). Further trials are evaluating its role in combination therapies for advanced NSCLC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The RAS-RAF-MEK-ERK pathway is crucial for cell proliferation and survival.
  • KRAS mutations activate this pathway in approximately 30% of non-small-cell lung cancer (NSCLC) cases.
  • Constitutive pathway activation drives tumor growth in NSCLC.

Purpose of the Study:

  • To review the development of selumetinib in NSCLC treatment.
  • To summarize selumetinib's pharmacodynamic, pharmacokinetic, and tolerability profiles.
  • To analyze clinical trial data for selumetinib's role in NSCLC.

Main Methods:

  • Review of preclinical and clinical studies on selumetinib in NSCLC.
  • Analysis of pharmacodynamic and pharmacokinetic data.
  • Evaluation of clinical trial outcomes, including efficacy and safety.

Main Results:

  • Selumetinib is a potent and selective MEK1/2 inhibitor.
  • It demonstrated efficacy in combination with docetaxel for pretreated, KRAS-mutant advanced NSCLC.
  • Ongoing trials explore selumetinib with various chemotherapy and targeted agents.

Conclusions:

  • Selumetinib is a promising targeted therapy for KRAS-mutant NSCLC.
  • Its combination potential with other regimens warrants further investigation.
  • Selumetinib may play a significant role in future NSCLC treatment strategies.
Keywords:
MEK inhibitornon-small-cell lung cancerselumetinib

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K